Business Wire

Ardoq Named to Denmark’s SKI Procurement Service for the Public Sector

9.1.2023 11:00:00 EET | Business Wire | Press release

Share

Ardoq, a SaaS company reinventing Enterprise Architecture (EA) for today’s digital enterprise, today announced that it has been named to Denmark’s SKI, which streamlines public procurement by establishing framework agreements that secure high quality services that can be purchased by organizations in the Danish public sector. Ardoq is currently the only provider of enterprise architecture software approved as a supplier on SKI.

Created to make public procurement more efficient, SKI aims to benefit the public sector by offering better solutions, higher quality and the best possible pricing for Danish public entities. With SKI’s pre-established frameworks and rigorous vetting process, public organizations can secure services without investing precious resources in lengthy net-new procurement processes as all organizations listed in the SKI purchasing and knowledge center have been pre-approved.

As an increasing number of public agencies adopt cloud technology, ensuring those new solutions meet the security and compliance needs of the public sector is critical. Because Ardoq is a SKI supplier, public entities can seamlessly adopt Ardoq’s EA tool with confidence that the company meets the stringent requirements government agencies require. With Ardoq, public entities can meet their transformation goals by building progressive EA that enables impactful decisions, provides business and IT transparency and delivers quick time-to-value.

“Public and private entities alike need next-gen, data-driven tools that allow them to drive successful transformation, improve change initiatives and save valuable resources,” said Lasse Berg, Director, EU, Ardoq. “Our inclusion in the SKI procurement service removes hurdles for public entities looking to harness the power of enterprise architecture to drive their organizations forward.”

Ardoq is currently available on SKI as a software supplier. To learn more, visit this page. To see how Ardoq is powering next generation EA, visit www.ardoq.com.

About Ardoq
Ardoq is a SaaS company reinventing Enterprise Architecture for today’s digital enterprise. The company’s dynamic, data-driven EA platform is designed to plan and execute major change initiatives. The tool provides a digital twin of an organization’s people, processes, systems, data, and infrastructure. With Ardoq, CIOs can confidently deliver digital transformations, and IT leaders can make better technology decisions based on real-time information. With Ardoq, EAs can serve as change agents, supporting business and IT collaboration for better outcomes. Learn more at www.ardoq.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Erin Cooper
ardoq@v2comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long

NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release

NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release

QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems

Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership15.9.2026 12:16:00 EEST | Press release

Axo Longevity today announced the close of an oversubscribed $5M seed round to expand its preventive health membership across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910642125/en/ Axo Longevity preventive health membership The round was backed by MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital and NIAN Sports & Entertainment, alongside angel investors including Dr. Jorge Planas of Clinica Planas Barcelona and Daniel Kulle, former President of H&M and former CEO of Forever 21. Developed to help people understand what is happening inside their body before symptoms appear, Axo Longevity moved from build to live operations in just twelve weeks. The platform is expanding globally, now operating in the United Kingdom, Ireland, Spain, Germany, and the Netherlands, as well as in its first Latin American market, Peru. It is supported by more than 1,400 laboratory

Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth15.9.2026 12:00:00 EEST | Press release

Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026. David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development. Following a thorough selection process led by the Board of Directors, David will succeed Interim Group CEO Jean-Marc Bellemin, who has successfully led the Group since 15 May 2026, while also continuing in his permanent role as Group CFO. Maria Paola Chiesi, Chiesi Group Chair, commented: “We are delighted to welcome David to Chiesi at a time of strong momentum for the company. Innovati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye